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Abstract 1 
Biocatalysis has become a powerful tool for the synthesis of high value compounds, 2 
particularly so in the case of highly functionalized and/or stereoactive products.  Nature 3 
has supplied thousands of enzymes and assembled them into numerous metabolic 4 
pathways.  While these native pathways can be use to produce natural bioproducts, there 5 
are many valuable and useful compounds which have no known natural biochemical 6 
route.  Consequently, there is a need for both unnatural metabolic pathways and novel 7 
enzymatic activities upon which these pathways can be built.  Here, we review the 8 
theoretical and experimental strategies for engineering synthetic metabolic pathways at 9 
the protein and pathway scales and highlight the challenges that this subfield of synthetic 10 
biology currently faces. 11 
12 
  
3 
Introduction 13 
Synthetic biology has emerged as a powerful discipline for the creation of novel 14 
biological systems (Endy, 2005; Pleiss, 2006), particularly within the subfield of 15 
metabolic pathway and product engineering (Keasling, 2008; Savage et al., 2008).  16 
Continuing efforts to characterize and understand natural enzymes and pathways have 17 
opened the door for the building of synthetic pathways towards exciting and beneficial 18 
compounds such as the anti-malarial drug precursor artemisinic acid (Ro et al., 2006) and 19 
several branched-chain alcohols for use as biofuels (Atsumi et al., 2007).  The need for 20 
synthetic metabolic routes is a consequence of the fact that the array of compounds of 21 
interest for biosynthesis vastly outnumbers the availability of characterized pathways and 22 
enzymes.  Several key building blocks can be made biologically (Patel et al., 2006); 23 
however, a recent report from the U.S. Department of Energy highlighted twelve 24 
biomass-derived chemical targets, only half of which have known biochemical routes 25 
(Werpy and Petersen, 2004). 26 
 27 
With the lack of characterized natural pathways to synthesize many high-value 28 
compounds, we must learn to forge our own metabolic routes towards these molecular 29 
targets.  Logically, it follows that for unnatural pathways, we will need new, unnatural 30 
enzymes from which these pathways can be composed.  The parts-devices framework of 31 
synthetic biology lends itself well to this dual-sided problem of synthetic pathway 32 
creation (Endy, 2005); that is, pathways can be thought of as metabolic devices 33 
composed of individual enzyme-catalyzed reaction parts.  Implicit within this framework 34 
is the idea that the challenges of pathway creation are best approached at both the part 35 
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and device levels.   In this review, we first discuss efforts at the protein-level for 36 
broadening the array of enzyme parts that can be recruited for use in synthetic pathways.  37 
The discussion is then expanded to pathway-level synthetic biology, where we review the 38 
tools available for designing metabolic pathways from enzyme-level parts and the 39 
implementation strategies for realizing these pathways experimentally.  The overall 40 
process of pathway creation (Figure 1) combines experimental and theoretical 41 
components of synthetic biology at both scales. 42 
 43 
Synthetic Biology at the Protein Scale 44 
Through natural evolution, organisms have acquired the capacity to catalyze a multitude 45 
of diverse chemical reactions as a means to proliferate in a wide range of unique 46 
microenvironments.  Although only a small fraction of the earth’s biodiversity (and an 47 
even smaller subset of its composite enzymes) has been characterized, the identification 48 
and isolation of novel proteins with unique properties or enzymatic function is a 49 
laborious procedure. One particularly promising source of new enzymes and enzymatic 50 
activities is the emerging field of metagenomics (Handelsman, 2004).  Nonetheless, the 51 
physical and catalytic properties of natural enzymes often render them as incompatible 52 
or, at the very least, unoptimized for use in engineered pathways and strains.  In cases 53 
where natural evolution has fallen short of industrial needs, the tools and practices of 54 
synthetic biology can be applied to aid in the creation of designer enzymes and cellular 55 
phenotypes.  The challenge of building new enzymes and reengineering natural ones has 56 
been approached with the development of predictive theoretical frameworks and a range 57 
of experimental techniques (Figure 2).   58 
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 59 
Theoretical Approaches 60 
Computational tools exist to adapt the natural array of proteins for use in an increasing 61 
number of applications.  For example, the effects of codon bias on expression levels 62 
(Kane, 1995; Gustafsson et al., 2004) can be resolved by design tools such as Gene 63 
Designer (Villalobos et al., 2006).  Other effects such as Shine-Dalgarno sequences, 64 
promoter strength, and mRNA stability can be similarly optimized.  Nonetheless, the 65 
application of these tools is still limited to the biochemical diversity found in nature.  To 66 
increase the number and efficiency of biologically-catalyzed reactions, more 67 
sophisticated in silico techniques are needed.  While full-scale protein folding and ab 68 
initio protein design and modeling are neither trivial nor currently practical, the use of 69 
solved protein structures, strong physical models and experimentally derived libraries 70 
allow for the design and improvement of enzymes.  These theoretically designed proteins 71 
in turn have significant potential to impact pathway-level synthetic metabolism 72 
(Yoshikuni et al., 2008). 73 
 74 
An empirical approach to synthetic protein design includes an understanding of the 75 
protein sequence/function relationship.  One example is the use of a linguistic metaphor 76 
to describe a protein sequence (Searls, 1997; Searls, 2002).  In language, a sentence is 77 
composed of a sequence of words whose parsed meaning is a function of not only their 78 
individual definitions but their connotations which are encoded by their type (part of 79 
speech) and their relative location to other words.  Similarly, a protein ‘sentence’ is 80 
composed of residues that have not only a definitive identity but also possess chemical 81 
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properties and a relative position that affect the subsequent fold and function of the 82 
resultant protein (Przytycka et al., 2002).  Building on the successes of a putative protein 83 
grammar (Przytycka et al., 2002; Naoki and Hiroshi, 1997), Loose et al. (2006) recently 84 
demonstrated its use in the design of new antimicrobial peptides.  Using the TEIRESIAS 85 
algorithm (Rigoutsos and Floratos, 1998), a library with homology to known sequences 86 
restricted to below 60% was generated with approximately 50% of designs showing some 87 
antimicrobial activity.  An alternative approach to modeling protein sequence/function 88 
relationships involves the use of folded protein scaffolds and quantum transition state 89 
models.  Through detailed crystal structures and transition state models, Hederos et al. 90 
(2004) noted that the active site of a glutathione transferase was of the appropriate size 91 
and structure to stabilize the transition state complex of the hydrolytic degradation of a 92 
thioester.  By introducing a histidine residue within the active site they were able to 93 
impart significant thioesterase activity.  Finally, physics based free energy approaches 94 
have been developed to predict protein structure/function relationships in the context of 95 
antibody binding strength.  While total free energy models were not a good predictor, 96 
Lippow et al. (2007) found that the electrostatic interaction contributions to total energy 97 
were well correlated with antibody binding affinity.  Using this relationship, they were 98 
able to generate an improved lysozyme antibody design which demonstrated a 140-fold 99 
increase in binding.  While neither of these examples fully describe protein 100 
structure/function relationships, each does offer a unique insight into the problem.  101 
Namely, they drastically reduced the sequence space of potential modifications to a 102 
manageable subset with a high probability of success.  In this manner, such empirical 103 
models serve as an important tool in the design and improvement of enzymes.   104 
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 105 
Using a quantum transition state framework, great strides have been made in the in silico 106 
development of enzyme activities (Jiang et al., 2008; Rothlisberger et al., 2008; Kaplan 107 
and Degrado, 2004).  At the heart of these efforts is a strong understanding of the desired 108 
catalytic mechanism and its associated transition states and reaction intermediates.  Once 109 
compiled, this information can be used to generate an active site of the appropriate 110 
dimensions with critical residues incorporated into appropriate locations for catalysis.  At 111 
this point, the designer has two options: try to identify a suitable folded scaffold that can 112 
accommodate the active site with minimal mutations or generate a protein backbone with 113 
correctly folded active site de novo.  Each method has its inherent advantages and 114 
challenges.   While finding a host scaffold would appear to be the simpler of the two, it 115 
requires extensive searches of protein structure libraries with tools such as RosettaMatch 116 
(Zanghellini et al., 2006).  Nonetheless, this approach has had some success with the 117 
catalysis of unnatural reactions such as the retro-aldol catalysis of 4-hydroxy-4-(6-118 
methoxy-2-naphthyl)-2-butanone (Jiang et al., 2008) and the Kemp elimination 119 
(Rothlisberger et al., 2008).  Coupled with experimental techniques, in silico designed 120 
enzymes can have activity levels comparable to that of evolved natural enzymes 121 
(Rothlisberger et al., 2008).  In contrast, de novo protein scaffold development requires 122 
significant computational effort to not only consider the stability of the desired 123 
conformation of the backbone and active site but also the likelihood of destabilization.  124 
Nonetheless, Kaplan and DeGrado (2004) have successfully used such an approach to 125 
generate an O2-dependent phenol oxidase.  Despite the computational overhead 126 
associated with these methods, their feasibility points to an improving and functional 127 
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understanding of protein structure/function relationships, leading to increased 128 
possibilities for the rational design of enzymes and proteins. 129 
 130 
In the absence of rational insight, theoretical tools can assist experimental techniques in 131 
generating new and improved proteins.  One common technique is protein recombination 132 
or in vitro shuffling which combines the best traits of two or more individual enzymes 133 
(Stemmer, 1994a; Stemmer, 1994b).  However, successful recombination is contingent 134 
on shuffling at domain boundaries to ensure proper folding of each domain.    The 135 
predictive algorithm SCHEMA, developed by Voigt et al. (2002), was designed to aid in 136 
the screening process of such chimeric proteins.  By analyzing the nature and number of 137 
the disruptions of the intermolecular interactions, Voigt et al. were able to generate a 138 
metric correlated with the probability of active -lactamase hybrids of TEM-1 and PSE-4 139 
(2002).  Subsequent studies by Meyer et al. (2003) have confirmed this correlation and 140 
used SCHEMA-guided recombination to derive functional and diverse libraries of 141 
cytochrome P-450s (Otey et al., 2004) and -lactamases (Meyer et al., 2006).  Another 142 
available predictive algorithm is FamClash (Saraf et al., 2004), which analyzes chimeras 143 
for the conservation of charge, volume and hydrophobicity at a given residue.  Generated 144 
sequence scores have been demonstrated to be well correlated with the activities of 145 
hybrid dihydrofolate reductases.  While experimental techniques are important generators 146 
of diverse protein libraries, tools such as FamClash, SCHEMA and other related 147 
sequence analysis programs enrich such chimeric libraries and vastly improve their value 148 
in the development of new and improved proteins.  Currently, these tools are incapable of 149 
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predicting hits a priori; however, their importance in successful protein design should not 150 
be underestimated. 151 
 152 
Experimental Approaches 153 
Rather than focusing on the prediction of protein structure and function, experimental 154 
techniques allow the improvement or modification of existing enzymes, in some 155 
instances creating entirely new enzymes and enzyme activities.  These techniques include 156 
mutagenesis, enzyme engineering and evolution, and gene synthesis technology, with 157 
each boasting their own distinct advantages and inherent limitations (Bonomo et al., 158 
2006; Alper and Stephanopoulos, 2007).  Collectively, they comprise a powerful set of 159 
tools for the efficient generation of enzymes with user-specified properties.  Protein 160 
recombination, for example, provides a means by which secondary structural elements, 161 
from natural or evolved proteins, can be rationally assembled in a modular fashion to 162 
integrate domains featuring desired attributes (Otey et al., 2004). 163 
 164 
The construction of synthetic pathways typically involves the recruitment of genes from 165 
an array of sources to provide the required enzymatic function and activity (Figure 1).  166 
However, heterologously expressed proteins, particularly those originating from a source 167 
organism belonging to a different kingdom than that of the expression host, often suffer 168 
from poor activity as a result of dissimilarities in codon usage.  In such cases, the use of 169 
synthetic genes with codon optimized sequences has been frequently employed to 170 
achieve sufficient levels of functional expression.  Synthesis of a codon optimized 171 
xylanase gene from Thermomyces lanuginosus DSM 5826 led to a 10-fold improvement 172 
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in expression level in E. coli (Yin et al., 2008).  Plant genes are often found to be poorly 173 
expressed in E. coli (Martin et al., 2001).  Martin et al. (2003) synthesized a codon 174 
optimized variant of amorpha-4,11-diene synthase from the Artemisia annua to catalyze 175 
the conversion of farnesyl pyrophosphate to amorphadiene, a precursor used for the 176 
production of the anti-malarial drug artemisinin.  As the cost associated with gene 177 
synthesis continues to decrease, imaginable applications of synthetic genes and artificial, 178 
designer proteins to include increased elements of rational design become increasingly 179 
plausible.  180 
 181 
The versatility of directed evolution for engineering desired enzyme attributes is 182 
highlighted by a multitude of recent works employing this approach for a diverse 183 
assortment of applications, including the enhancement of thermal stability (Asako et al., 184 
2008; Shi et al., 2008) and acid tolerance (Liu et al., 2008); promoting higher chemo-, 185 
regio-, and enantio-selectivity towards substrates (Asako et al., 2008); elimination of 186 
undesired biochemical activities (e.g., side reactions; Kelly et al., 2008); and improving 187 
heterologous expression (Mueller-Cajar et al., 2008).  In the example of the stereospecific 188 
reduction of 2,5-hexanedione to (2S,5S)-hexanediol by alcohol dehydrogenase (AdhA) 189 
from the thermophillic bacteria Pyrcoccus furiosus, laboratory evolution was used by 190 
Machielsen et al. (2008) to alter the enzyme’s optimum temperature and improve its 191 
activity in recombinant E. coli under moderate culture conditions.  Meanwhile, Aharoni 192 
et al. (2004) have achieved functional expression of mammalian paraoxonases PON1 and 193 
PON3 in E. coli through a directed evolution scheme that incorporated family DNA 194 
shuffling (shuffling of DNA encoding homologous genes from different genetic sources) 195 
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and random mutagenesis to achieve the first active microbial expression of recombinant 196 
PON variants.  As a tool, directed evolution continues to benefit from refinements aimed 197 
at improving the efficiency at which desired mutations can be obtained from a minimal 198 
number of iterations while also reducing screening efforts (Reetz et al., 2007; Reetz et al., 199 
2008).  200 
 201 
In addition to improving expression and altering the thermal properties of heterologous 202 
enzymes, novel biochemical activities can be similarly engineered by the aforementioned 203 
strategies.  For example, cytochrome P450 BM3 from Bacillus megaterium has been 204 
engineered via directed evolution using several sequential rounds of mutagenesis to alter 205 
its regioselectivity for the hydroxylation of n-alkanes from subterminal positions to that 206 
of the terminus (Meinhold et al., 2006).  The approach has been employed to convert 207 
several different n-alkanes to their corresponding n-alcohols, including the hydroxylation 208 
of ethane to ethanol as a means for producing more tractable transportation fuels from 209 
petrochemical feedstocks (Meinhold et al., 2005).  To promote high end-product 210 
specificity while maximizing metabolite flux, the preferential activity of an enzyme 211 
between multiple competing substrates can also be tailored.  For instance, the substrate 212 
specificity of pyruvate oxidase (PoxB) from E. coli was altered via localized random 213 
mutagenesis to decrease its activity on pyruvate in favor of an alternative endogenous 214 
metabolite, 2-oxo-butanoate (Chang and Cronan, 2000).  Synthetic pathways 215 
incorporating this PoxB mutant will accordingly display preferential synthesis of 216 
products from the four-carbon precursor.  Meanwhile, Tsuge et al. (2003) utilized site 217 
directed mutagenesis to shift the substrate specificity of PhaJ, an R-specific enoyl-CoA 218 
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hydratase from Aeromonas caviae from short-chain 3-hydroxyacyl-CoA precursors 219 
towards those with longer carbon chain lengths (8 to 12).  When incorporated into an 220 
engineered polyhydroxyalkanoate (PHA) synthesis pathway in E. coli, increased molar 221 
fractions of C8 and C10 3-hydroxyacid monomer units were found to be incorporated into 222 
PHA.   In this case, the capacity to distinctly manipulate the composition of PHAs makes 223 
possible the synthesis of novel bio-plastics with customizable physical properties to meet 224 
commercial requirements.  The ability to finely tune the substrate specificity of an 225 
engineered enzyme is of particular importance for promoting high selectivity and product 226 
yield, as well as for reducing the ill-effects of molecular cross-talk between engineered 227 
and endogenous pathways.   228 
 229 
At the protein level, synthetic biology aims to expand the catalog of well-characterized 230 
enzymes while also engineering novel biochemistries.  Subsequent incorporation of 231 
engineered enzymes into synthetic pathways leads to the construction of devices that can 232 
be implemented to achieve a user-specified function, such as the production of biofuels or 233 
high-value pharmaceutical compounds.  The design and construction of new metabolic 234 
routes from individual enzymes represents synthetic biology at the next scale, the 235 
pathway scale, and has unique challenges of its own.   236 
 237 
Synthetic Biology at the Pathway Scale 238 
Pathway-scale synthetic biology aims to create novel metabolic routes towards both 239 
existing metabolites and unnatural compounds.  Traditionally, pathway engineering has 240 
been synonymous with metabolic engineering and its toolbox has been composed of the 241 
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same tools: gene knockouts, flux optimization, gene overexpression, and the like.  The 242 
ability to manipulate natural metabolism has seen many useful applications, such as 243 
improving ethanol production in Saccharomyces cerevistiae (Bro et al. 2006), 244 
solventogenesis in Clostridium acetobutylicum (Mermelstein et al., 1993; Woods, 1995), 245 
and penicillin production in Penicillium chrysogenum (Casqueiro et al., 2001).  A key 246 
limitation in all of these examples is the confinement of pathway engineering to the 247 
manipulation of natural metabolism.  Continuing advances in characterizing, modifying, 248 
and even creating enzymes (several of them discussed in the previous section of this 249 
review) now allow us to build unnatural pathways for the biological production of 250 
compounds.  Understanding synthetic biology at the protein scale affords us the 251 
opportunity to apply it at the pathway scale. 252 
 253 
As at the protein scale, pathway-level synthetic biology has been approached from both 254 
theoretical and experimental fronts.  The theoretical work centers on the concept of 255 
pathway design – assembling a logical series of enzyme-catalyzed reactions to convert an 256 
accessible substrate into a valued final compound.  Theoretical pathway design probes 257 
what conversions are possible and what enzyme parts need to be assembled to create a 258 
functional metabolic device.  In contrast, experimental efforts focus on the construction 259 
and application of unnatural pathways and serve as powerful real-world examples of what 260 
these pathways can accomplish.  Experimental approaches enable the exploration of 261 
enzyme behaviors such as substrate promiscuity and activity, both useful properties for 262 
creating unnatural pathways that cannot readily be predicted with theoretical approaches. 263 
 264 
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Theoretical Approaches 265 
Before an unnatural metabolic pathway can be built in the laboratory, it must first be 266 
designed.  The goal of pathway design is to use a series of biochemically-catalyzed 267 
reactions to connect a target product molecule to either a cellular metabolite (such as 268 
acetyl-CoA, α-ketoglutarate, or L-alanine) or to a feasible feedstock (such as glucose or 269 
glycerol).  This can be accomplished using either natural enzymes or engineered ones.  270 
The sheer number of known enzymes (both natural and engineered) and enzyme-271 
catalyzed reactions available means that there will almost certainly exist many possible 272 
theoretical pathways towards a given target compound (Li et al., 2004; Hatzimanikatis et 273 
al., 2005).  Identifying and ranking these different possibilities are the central challenges 274 
in pathway design. 275 
 276 
One of the first steps in pathway design is obtaining knowledge of the enzymes and 277 
enzyme-catalyzed reactions available for use in a pathway.  Comprehensive protein and 278 
metabolism databases, such as BRENDA (Schomburg et al., 2004), KEGG (Kaneshisa et 279 
al., 2006), Metacyc (Capsi et al., 2006), and Swiss-Prot (Wu et al., 2006), provide a 280 
wealth of information on the pool of natural, characterized enzymes that can be recruited.  281 
More importantly, these databases reveal chemical conversions that are achievable with 282 
enzymes.  As of the preparation of this manuscript, there are approximately 398,000 283 
protein entries in Swiss-Prot (build 56.2), from which the enzymes are organized into 284 
4757 four-digit enzyme classification (E.C.) groups in the most recent version of 285 
BRENDA (build 2007.2).  Because of the large number of characterized enzymes, those 286 
performing similar reaction chemistries are typically organized into generalized enzyme-287 
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catalyzed reactions for the purposes of pathway construction (Li et al., 2004).  A 288 
generalized enzyme-catalyzed reaction is defined as the conversion of one functional 289 
group or structural pattern in a substrate into a different group or structure in its product 290 
(Figure 3).  Structural information about the non-reacting portions of the substrate is 291 
ignored, making the identification of enzymes to carry out a desired chemical conversion 292 
a much more tractable problem.  However, the logical rules for assigning enzymes to a 293 
generalized reaction can be subjective (Figure 3).  One could for instance differentiate 294 
between reactions solely on the reacting functional groups (i.e. aldehyde to alcohol) as Li 295 
and coworkers (2004) did, or one could also include information about conserved 296 
patterns of molecular structure between similar enzyme-catalyzed reactions.  297 
Furthermore, generalized enzymatic reactions do not all fall cleanly into the existing E.C. 298 
system (Figure 3c). 299 
 300 
Despite the need for a universal standard in reaction generalization, several publically-301 
available tools utilize this approach to address the problem of pathway design.  The 302 
BNICE (Biochemical Network Integrated Computational Explorer) framework allows for 303 
the discovery of numerous possible metabolic routes between two compounds (Li et al., 304 
2004; Hatzimanikatis et al., 2005).  This framework was applied to aromatic amino acid 305 
biosynthesis to find over 400,000 theoretical biochemical pathways between chorismate 306 
and phenylalanine, tyrosine, or tryptophan (Hatzimanikatis et al., 2005) and it was used 307 
to explore thousands of novel linear polyketide structures (González-Lergier et al., 2005).  308 
Our group has developed a database of over 600 conserved structure generalized enzyme-309 
catalyzed reactions called ReBiT (Retro-Biosynthesis Tool, http://www.retro-310 
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biosynthesis.com) which accepts as input a molecular or functional group structure and 311 
returns as output all 3-digit E.C. groups capable of reacting with or producing that 312 
structure.  The University of Minnesota Biocatalysis/Biodegradation Database (UM-313 
BBD) uses a series of generalized reaction rules to propose pathways step by step, with 314 
particular emphasis on analyzing the degradation trajectories of xenobiotics (Ellis et al., 315 
2006; Fenner et al., 2008). 316 
 317 
Typically multiple, and indeed in some cases, several thousand, metabolic routes can be 318 
proposed for a given compound.  How does one distinguish logical, feasible pathways 319 
from frivolous, improbable ones?  What metrics can be applied to judge one 320 
computationally-generated pathway as superior (i.e. more likely to be functionally 321 
constructed) to another?   One way of narrowing the choice of pathways is to apply 322 
natural precedent to filter out unlikely pathway steps.  In this strategy, a large set of 323 
experimentally validated enzyme-catalyzed reactions are examined for patterns of 324 
structural change and a series of rules are developed to give preference to reaction steps 325 
containing structural changes that follow these rules.  This methodology is implemented 326 
in the UM-BBD to avoid the “combinatorial explosion” that results when considering all 327 
the possible pathways that any given compound can take (Fenner et al., 2008).  Another 328 
ranking strategy is to calculate the thermodynamic favorability of the steps and to 329 
penalize pathways involving steps which are energetically unfavorable.  This approach is 330 
taken by the BNICE framework (Hatzimanikatis et al., 2005) using a functional group 331 
contribution method (Jankowski et al., 2008) to compute the overall change in Gibbs 332 
energy for each individual pathway step.  A new pathway modeling tool, DESHARKY, 333 
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quantifies and employs metabolic burden as a metric for judging unnatural pathways and, 334 
in particular, how they are connected to cellular metabolism (Rodrigo et al., 2008).  335 
DESHARKY is a Monte Carlo-based algorithm that estimates the transcriptomic and 336 
metabolic loads on cells expressing unnatural pathways and calculates the decrease in 337 
specific growth rate as a result of these additional burdens.  There are still other 338 
possibilities for pathway ranking, such as the number of pathway steps taken, the known 339 
substrate specificities (or lack thereof) of the enzymes involved in each pathway, or the 340 
availability and diversity of homologous enzymes to test at each pathway step.  One of 341 
the key challenges in pathway design is scoring pathways in a robust and balanced 342 
manner, and only as more non-natural pathways are designed and built will there be a 343 
better understanding as to which of these metrics are relevant and useful. 344 
 345 
Experimental Approaches 346 
With a target compound and a proposed metabolic route to reach that compound in hand, 347 
one is now ready to begin experimental implementation of that pathway.  Synthetic 348 
pathway construction occurs over several shades of novelty – from recreating natural 349 
pathways in heterologous hosts to creating synthetic pathways that parallel natural ones 350 
to building completely novel metabolic routes towards unnatural compounds from 351 
multiple, ordinarily unrelated enzymes (Figure 4).  Here we discuss the situations in 352 
which non-natural pathways prove useful and several general strategies for creating these 353 
pathways. 354 
 355 
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Through the course of evolution, nature has assembled many pathways towards several 356 
useful compounds, such as the biofuel and solvent 1-butanol in Clostridium 357 
acetobutylicum (Jones and Woods, 1986; Dürre et al., 2002; Lee et al., 2008), the C5 358 
terpenoid building block isopentenyl pyrophosphate (IPP) in Saccharomyces cerevisiae 359 
(Seker et al., 2005), and the biopolymer polyhydroxybutyrate (PHB) in Ralstonia 360 
eutropha (Wang and Yu, 2007).  These pathways have physiological roles within their 361 
native hosts; for example, the butanol pathway from acetyl-CoA in C. acetobutylicum 362 
serves as an electron sink to regenerate NAD
+
 for glycolysis while deacidifying its 363 
environment (Jones and Woods, 1986).  Pathways in nature are optimized through 364 
evolution to accomplish their physiological objectives, yet in most cases of pathway 365 
engineering, it is desired to maximize the production of a target molecule in a pathway 366 
rather than to accomplish a physiological goal.  Butanol production in C. acetobutylicum, 367 
for instance, is constricted by cellular regulation tying it to pH, redox conditions, and 368 
sporulation (Dürre et al., 2002; Lee et al., 2008).  The transference of natural pathways 369 
into heterologous hosts isolates these pathways from their regulatory elements and 370 
represents a first small step towards the creation of non-natural metabolism.  While 371 
heterologous pathway expression is limited to only pathways found in nature, it 372 
nonetheless has proven effective in enhancing product titers and/or deregulating 373 
compound production for a wide array of products, including the compounds in the 374 
examples above (Atsumi et al., 2007; Kang et al., 2008; Martin et al., 2003; Pitera et al., 375 
2007).   376 
 377 
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The next level of novelty in synthetic pathway construction is creating metabolic routes 378 
that parallel natural pathways, typically by capitalizing on enzymatic promiscuity or 379 
enzyme engineering to operate natural or near-natural pathways on non-natural 380 
substrates.  This pathway construction strategy allows for the biosynthesis of truly 381 
unnatural compounds.  Returning to the PHB example, recombinant R. eutrophia have 382 
been shown to incorporate sulfur-containing short- and medium-chain length thioacids 383 
into polythioester co-polymers (Ewering et al., 2002).  The synthesis of these completely 384 
unnatural polymers was made possible by taking advantage of the relatively broad 385 
substrate specificity of polyhydroxyalkanoate (PHA) synthases (Hazer and Steinbüchel, 386 
2007), and because of that broad substrate specificity, hundreds of different monomer 387 
units of various sizes (C3-C16) and substituents have been incorporated into PHA co-388 
polymers (Steinbüchel and Valentin, 1995).  Another example of parallel pathway 389 
construction is the synthesis of triacetic acid lactone from acetyl-CoA by expressing an 390 
engineered fatty acid synthase B from Brevibacterium ammoniagenes (Zha et al., 2004).  391 
This multifunctional enzyme has many domains designed to catalyze the various 392 
reductions and condensations necessary for fatty acid synthesis (Meurer et al., 1991).  By 393 
specifically inactivating the ketoacyl-reductase domain of this fatty acid synthase, the 394 
enzyme could no longer use NADPH to reduce its acetyl-CoA condensation products, 395 
causing them to circularize into triacetic acid lactone rather than forming linear fatty 396 
acids.  Finally, natural products can be synthesized by arranging whole or partial 397 
pathways to form a mixed, synthetic metabolic route.  For example, the theoretical yield 398 
of L-glutamate was improved from 1 mol glutamate per mol glucose to 1.2 mol per mol 399 
by augmenting the native Corynebacterium glutamicum pentose phosphate pathway with 400 
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a phosphoketolase from Bifidobacterium lactis (Chinen et al., 2007).  This strategy 401 
allowed for the production of acetyl-CoA without the loss of carbon caused by pyruvate 402 
decarboxylation to acetyl-CoA and resulted in increased glutamate titers and 403 
productivity. 404 
 405 
One of the most promising (and challenging) strategies for building synthetic pathways is 406 
de novo pathway construction:  the creation of pathways using disparate enzymes to form 407 
entirely unnatural metabolic routes towards valuable compounds.  This method of 408 
pathway building does not rely upon natural precedent, but rather allows one to build 409 
entirely new metabolite conduits from individual enzymatic pieces.  As a result, this 410 
approach allows for the biosynthesis of the widest array of compounds.  On the other 411 
hand, this strategy is the most difficult to realize given that for a completely unnatural 412 
pathway, there may not be a complete set of appropriate known enzymes in nature to 413 
build it.  De novo pathway construction illustrates the need for a more complete set of 414 
enzymatic tools for use in building synthetic pathways, and frequently this strategy is 415 
coupled with enzyme engineering or the exploitation of enzymatic promiscuity to 416 
compensate for the absence of a natural enzyme to execute a desired conversion step. 417 
 418 
Because of the challenge in creating functional de novo pathways, few examples exist.  419 
However, those that are available describe the biosynthesis of a wide range of useful 420 
compounds and illustrate the utility of the approach.  For instance, a pathway for the 421 
biosynthesis of 1,2,4-butanetriol from D-xylose and L-arabinose was assembled using 422 
pentose dehydrogenases and dehydratases from Pseudomonas fragi and E. coli and 423 
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benzoylformate decarboxylase from Pseudomonas putida (Nui et al., 2003).  In this case, 424 
multiple decarboxylases were screened to find a promiscuous decarboxylase from P. 425 
putida capable of acting on a 3-deoxy-glyceropentulosonic acid intermediate in the 426 
pathway.  Another example of exploiting substrate promiscuity in de novo pathway 427 
design is in the synthesis of several higher biofuels such as 2-methyl-1-butanol, 428 
isobutanol, and 2-phenylethanol from glucose in E. coli (Atsumi et al., 2007).  Here, 429 
several 2-keto-acid decarboxylases were screened to identify one from Lactococcus lactis 430 
for use in creating alcohols from 2-ketoacids (when combined with native E. coli alcohol 431 
dehydrogenase activity).  In a third example, a synthetic pathway for the unnatural 432 
aminoacid phenylglycine from phenylpyruvate was made by combining 433 
hydroxymandelate synthase, hydroxymandelate oxidase, and D-(4-434 
hydroxy)phneylglycine aminotransferase activities from Amycolatopsis orientalis, 435 
Streptomyces coelicolor, and P. putida (Müller et al., 2006).  Finally, engineered 436 
enzymes can be employed to create de novo pathways, as in the recent case of the 437 
synthesis of 3-hydroxypropionic acid from alanine in E. coli (Liao et al., 2007).  Here, a 438 
lysine 2,3-aminomutase from Porphyromonas gingivalis (Brazeau et al., 2006) was 439 
evolved to have alanine 2,3-aminomutase activity, allowing for the biosynthesis of β-440 
alanine.  Combining this evolved enzyme with β-alanine aminotransferase and 441 
endogenous alcohol dehydrogenase activities afforded the final 3-hydroxypropionic acid 442 
product.  Another very recent work utilizes engineered pyruvate decarboxylase and 2-443 
isopropylmalate synthase for the synthesis of non-natural alcohols from 2-ketoacids in E. 444 
coli (Zhang et al., 2008).  By engineering the enzymes responsible for elongating 2-445 
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ketoacids and carrying out their decarboxylation and reduction, the production of a 446 
broader array of longer-chain alcohols was enabled. 447 
 448 
Conclusions 449 
The design and assembly of unnatural metabolic pathways represents a young and 450 
exciting field with the potential to supplement, expand upon, or even replace current 451 
industrial processes for the production of fine and commodity chemicals.  Synthetic 452 
pathway engineering integrates many components and consequently is highly 453 
interdisciplinary (Figure 1).  Key issues that need to be overcome in pathway design are 454 
(1) establishing a standard for generalized enzyme-catalyzed reactions, (2) capturing 455 
enzyme substrate preferences in these generalized reactions, and (3) determining the 456 
pathway metrics that correlate with successful pathway construction.  Overcoming the 457 
first two challenges will allow for the creation of the next generation of pathway design 458 
tools that better account for enzyme behavior, while conquering the last challenge will 459 
afford us the ability to rank and choose metabolic pathways and refine the results from 460 
design tools.  For experimentally implementing unnatural pathways, the central challenge 461 
is the limited number of characterized enzymes for the construction of new pathways.  In 462 
particular, there is great demand for both promiscuous natural enzymes and engineered 463 
enzymes to perform specific desired reactions. 464 
 465 
The need for new enzymes has given rise to several theoretical frameworks for relating 466 
protein sequence, structure, and function.  These frameworks each address a piece of the 467 
problem – energetics, active site catalysis, and protein backbone structure, etc. – but the 468 
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ability to routinely build whole enzymes is still in the distant future.  In the meantime, 469 
mimicking active sites, backbones, and protein linguistics from nature has proven fruitful 470 
in creating novel proteins.  Experimental evolution and chimeragenesis of enzymes are 471 
standard ways of imparting unnatural properties, particularly in the absence of detailed 472 
information about the protein.  The power of these experimental techniques is primarily 473 
limited by the size of the resulting enzyme libraries and the throughput of the screen to 474 
analyze them.  Computational tools such as SCHEMA (Voigt et al., 2002) and Famclash 475 
(Saraf et al., 2004) can assist in focusing and enriching these libraries.  476 
 477 
As biotechnology is increasingly relied upon as a means for chemical production, 478 
progress on the creation of new enzymes and unnatural pathway design and construction 479 
will flourish.  These new pathways must still be expressed within a cellular context, thus 480 
improving and understanding unnatural pathway efficacy at a systems level will be 481 
important for shattering barriers in pathway expression and product titer.  For example, 482 
application of flux balance analysis (Edwards et al., 2002) can guide systems-level 483 
integration of non-natural pathways with host metabolism.  Furthermore, redox balancing 484 
and cofactor regeneration with respect to new pathways are critical to minimize their 485 
burden on the host cell (Endo and Koizumi, 2001).  Systems-level functionality can also 486 
be coupled with unnatural pathways, for instance in the delivery of recombinant microbes 487 
to a cancerous tumor (Anderson et al., 2006).  Such microbes could be engineered to 488 
simultaneously produce and deliver a drug.  Established and recent advances in metabolic 489 
engineering, such as global transcription machinery engineering (Alper and 490 
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Stephanopoulos, 2007), can complement synthetic biology in this regard, leading to 491 
improved performance of novel pathways.    492 
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Figure Captions 827 
Figure 1:  Overall scheme for pathway creation.  The creation process includes protein-level recruitment 828 
and reengineering of enzymes and pathway-level efforts to design and assemble these enzymes into an 829 
unnatural pathway. 830 
 831 
Figure 2:  Flowchart for the creation of new enzymes with experimental techniques and computational 832 
tools.  New enzymes generated with these methods are examined for desired properties and either further 833 
reengineered or adapted for use in unnatural pathways. 834 
 835 
Figure 3:  Generalized enzyme-catalyzed reactions for a subset of E.C. 1.1.1 alcohol dehydrogenases (3a), 836 
E.C. 4.3.1 ammonia-lyases (3b), and E.C. 2.5.1 synthases (3c).  The “A” atoms present in the molecular 837 
structures are wildcards.  In Figure 3a, two different methods of assigning generalized reactions, one 838 
considering only the reacting parts of the molecule (core generalized reaction) and one identifying patterns 839 
of conserved molecular structure in addition to the reacting structural elements (conserved structure 840 
generalized reaction), arrive at the same generalized reaction.  In Figure 3b, the two methods arrive at 841 
different generalized reactions, illustrating the need for a generalization standard.  In Figure 3c, a set of five 842 
enzymes within a three-digit E.C. class result in two different sets of generalized reactions, illustrating that 843 
the E.C. system does not necessarily correlate with reaction generalization. 844 
 845 
Figure 4:   846 
Strategies for synthetic pathway creation arranged in increasing degrees of departure from nature.  A, B, C, 847 
D, F, α, β, γ, and Δ represent metabolites, E represents an enzyme catalyzing a reaction, and ε represents an 848 
engineered enzyme catalyzing a reaction.  In (1), a natural pathway in its native host is transferred to a 849 
heterologous host, decoupling it from native regulation.  This strategy is limited to the production of natural 850 
products using natural pathways.  In (2), new pathways are made in parallel to natural ones through the use 851 
of promiscuous enzymes (2a), enzyme engineering (2b), or combinations of natural pathways (2c).  852 
Strategies 2a and 2b allow for the synthesis of new, non-natural products, while 2c allows for the creation 853 
of new metabolic routes between natural metabolites.  Strategy 3 represents de novo pathway construction, 854 
  
41 
where individual unrelated enzymes are recruited to form entirely unnatural pathways.  This can be done 855 
using native enzyme activities (3a), promiscuous enzymes (3b), engineered enzymes (3c), or combinations 856 
thereof. 857 
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Figure 3a.  867 
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Figure 3b.  871 
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Figure 3c.  875 
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Figure 4.  879 
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